The anticancer effect of PQ1 in the MMTV-PyVT mouse model

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1474-1483

  Shishido, Stephanie N ^a   Delahaye, Adélaïde ^a   Beck, Amanda ^a   Nguyen, Thu Annelise ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

connexin; gap junctions; MMTV PyVT; PQ1

Indexed keywords

6 METHOXY 8 [(3 AMINOPROPYL)AMINO] 4 METHYL 5 (3 TRIFLUOROMETHYL PHENYLOXY)QUINOLONE; CONNEXIN 43; CONNEXIN 46; GAP JUNCTION PROTEIN; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL COMMUNICATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; GAP JUNCTION; HISTOPATHOLOGY; METASTASIS; METASTASIS INHIBITION; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR VOLUME;

EID: 84891836589     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28461     Document Type: Article

References (43)

1. Loewenstein WR, Kanno Y,. Intercellular communication and the control of tissue growth: lack of communication between cancer cells. Nature 1966; 209: 1248-9.
2. Loewenstein WR, Kanno Y,. Intercellular communication and tissue growth. I. Cancerous growth. J Cell Biol 1967; 33: 225-34.
3. Loewenstein WR,. Junctional intercellular communication and the control of growth. Biochim Biophys Acta 1979; 560: 1-65.
4. Mesnil M,. Connexins and cancer. Biol Cell 2002; 94: 493-500.
5. Murray AW, Fitzgerald DJ,. Tumor promoters inhibit metabolic cooperation in cocultures of epidermal and 3T3 cells. Biochem Biophys Res Commun 1979; 91: 395-401.
6. Klaunig JE, Ruch RJ,. Strain and species effects on the inhibition of hepatocyte intercellular communication by liver tumor promoters. Cancer Lett 1987; 36: 161-8.
7. Shi A, Nguyen TA, Battina SK, et al. Synthesis and anti-breast cancer activities of substituted quinolines. Bioorg Med Chem Lett 2008; 18: 3364-8.
8. Gakhar G, Ohira T, Shi AB, et al. Antitumor effect of substituted quinolines in breast cancer cells. Drug Dev Res 2008; 69: 526-34.
9. Ding Y, Prasain K, Nguyen TD, et al. The effect of the PQ1 anti-breast cancer agent on normal tissues. Anti-Cancer Drugs, 2012; 23: 897-905.
10. Shishido SN, Nguyen TA,. Gap junction enhancer increases efficacy of cisplatin to attenuate mammary tumor growth. PLoS One 2012; 7: e44963.
11. Guy CT, Cardiff RD, Muller WJ,. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992; 12: 954-61.
12. Lin EY, Jones JG, Li P, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003; 163: 2113-26.
13. Maglione JE, Moghanaki D, Young LJ, et al. Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001; 61: 8298-305.
14. Bukauskas FF, Verselis VK,. Gap junction channel gating. Biochim Biophys Acta 2004; 1662: 42-60.
15. Lampe PD, Lau AF,. The effects of connexin phosphorylation on gap junctional communication. Int J Biochem Cell Biol 2004; 36: 1171-86.
16. Peracchia C,. Chemical gating of gap junction channels; roles of calcium, pH and calmodulin. Biochim Biophys Acta 2004; 1662: 61-80.
17. Liu J, Ek Vitorin JF, Weintraub ST, et al. Phosphorylation of connexin 50 by protein kinase A enhances gap junction and hemichannel function. J Biol Chem 2011; 286: 16914-28.
18. Musil LS, Goodenough DA,. Biochemical analysis of connexin43 intracellular transport, phosphorylation, and assembly into gap junctional plaques. J Cell Biol 1991; 115: 1357-74.
19. Hawat G, Baroudi G,. Differential modulation of unapposed connexin 43 hemichannel electrical conductance by protein kinase C isoforms. Pflugers Archiv: Eur J Physiol 2008; 456: 519-27.
20. Adida C, Crotty PL, McGrath J, et al. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998; 152: 43-9.
21. Altieri DC,. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
22. Ambrosini G, Adida C, Altieri DC,. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
23. Dohi T, Beltrami E, Wall NR, et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114: 1117-27.
24. Heiniger B, Gakhar G, Prasain K, et al. Second-generation Substituted Quinolines as Anticancer Drugs for Breast Cancer. Anticancer Res 2010; 30: 3927-32.
25. Banerjee D, Gakhar G, Madgwick D, et al. A novel role of gap junction connexin46 protein to protect breast tumors from hypoxia. Int J Cancer 2010; 127: 839-48.
26. Hirschi KK, Xu CE, Tsukamoto T, et al. Gap junction genes Cx26 and Cx43 individually suppress the cancer phenotype of human mammary carcinoma cells and restore differentiation potential. Cell Growth Differ: Mol Biol J Am Assoc Cancer Res 1996; 7: 861-70.
27. Burr DB, Molina SA, Banerjee D, et al. Treatment with connexin 46 siRNA suppresses the growth of human Y79 retinoblastoma cell xenografts in vivo. Exp Eye Res 2011; 92: 251-9.
28. Sui L, Dong Y, Ohno M, et al. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 2002; 21: 315-20.
29. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-34.
30. Zaffaroni N, Pennati M, Colella G, et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci: CMLS 2002; 59: 1406-12.
31. Swana HS, Grossman D, Anthony JN, et al. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. New Engl J Med 1999; 341: 452-3.
32. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991; 138: 867-73.
33. Railo M, Nordling S, von Boguslawsky K, et al. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 1993; 68: 579-83.
34. Mesnil M, Crespin S, Avanzo JL, et al. Defective gap junctional intercellular communication in the carcinogenic process. Biochim Biophys Acta 2005; 1719: 125-45.
35. Saunders MM, Seraj MJ, Li Z, et al. Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 2001; 61: 1765-7.
36. Akoyev V, Takemoto DJ,. ZO-1 is required for protein kinase C gamma-driven disassembly of connexin 43. Cell Signal 2007; 19: 958-67.
37. Morley M, Jones C, Sidhu M, et al. PKC inhibition increases gap junction intercellular communication and cell adhesion in human neuroblastoma. Cell Tissue Res 2010; 340: 229-42.
38. Lee F, Hall CV, Ringold GM, et al. Functional analysis of the steroid hormone control region of mouse mammary tumor virus. Nucleic Acids Res 1984; 12: 4191-206.
39. Kitsberg DI, Leder P,. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene 1996; 13: 2507-15.
40. Ristevski S,. Making better transgenic models: conditional, temporal, and spatial approaches. Mol Biotechnol 2005; 29: 153-63.
41. Zhu D, Kidder GM, Caveney S, et al. Growth retardation in glioma cells cocultured with cells overexpressing a gap junction protein. Proc Natl Acad Sci USA 1992; 89: 10218-21.
42. Ruch RJ,. The role of gap junctional intercellular communication in neoplasia. Ann Clin Lab Sci 1994; 24: 216-31.
43. Saez CG, Velasquez L, Montoya M, et al. Increased gap junctional intercellular communication is directly related to the anti-tumor effect of all-trans-retinoic acid plus tamoxifen in a human mammary cancer cell line. J Cell Biochem 2003; 89: 450-61.